Miyasato Y, Oba K, Masuda I, Mukoyama M. Investigation of the effect of visceral fat on the chronic kidney disease development and progression in medical checkup participants. 29th Scientific Meeting of the International Society of Hypertension (ISH), Kyoto, Japan, October 12-16, 2022.
Fuyama K, Ogawa M, Mizusawa J, Oba K. Impact of correlations between prioritized outcomes on the net benefit and its estimate by generalized pairwise comparisons, WNAR/IMS, Online, 2022, June 10-15, 2022.
Oba K, Paoletti X, Bang YJ, et al. Progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in advanced/recurrent gastric cancer (AGC) treatment: Individual-patient-data (IPD) based meta-analysis of randomized trials. Annual Meeting of ASCO2020, Online, June 4-6, 2020.
Asano-Inagaki A, Fukui C, Igarashi A, Sakka M, Noguchi-Watanabe M, Eltaybani, S, Takeuchi Y, Yamamoto-Mitani N. The effectiveness of homecare nursing use to reduce the incidence of potentially avoidable hospitalization among community-dwelling older adults in Japan : A 12-month prospective cohort study. IAGG Asia/Oceania Regional Congress 2023, Yokohama, 2023 Jun.
Kato L, Eltaybani S, Shinohara M, Igarashi A, Sumikawa Y, Inagaki A, Takeuchi Y, Yamamoto-Mitani N. Prognostic effect of body mass index on the incidence of unfavorable physical health outcomes among older adults receiving home care nursing: A prospective cohort study. IAGG Asia/Oceania Regional Congress 2023, Yokohama, 2023 Jun.
Kumamaru H, Takeuchi Y, Kohsaka S, Matsui H, Yasunaga H, Miyata H. Comparative effectiveness of First-line SGLT2 inhibitor use on heart failure hospitalization among patients with type 2 diabetes mellitus; A target trial emulation (Poster presentation). 38th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. 2022 Aug, Copenhagen/Online.
Takeuchi Y, Iwagami M, Ono S, Yasunaga H. Serious adverse effects after COVID-19 vaccination in Japan: Analysis using administrative claims data linked with vaccination registry. 14th Asian Conference on Pharmacoepidemiology. 2022 Oct, Tainan/Online.
Takada M, Shigehira Saji, Takayuki Ueno, Norikazu Masuda, Hiroshi Ishiguro, Takanori Ishida, Toshiaki Saeki, Shigeru Imoto, Shinji Ohno, Yoshinori Ito, Hiroji Iwata, Tomoharu Sugie, Kenjiro Aogi, Hirofumi Mukai, Shin Takayama, Nobuaki Sato, Yuichiro Kai, Masahiro Kitada, Yutaka Matsuyama, Masakazu Toi. Adjuvant S-1 plus endocrine therapy for estrogen receptor-positive, HER2-negative, primary breast cancer: update overall survival analysis from the POTENT trial. SABCS2022. 45th San Antonio Breast Cancer Symposium. 12/6/2022 - 12/10/2022.
Yoshikuni Kawaguchi, Ryuichi Kita, Toru Kimura, Tadatoshi Takayama, Namiki Izumi, Masatoshi Kudo, Shuichi Kaneko, Naoki Yamanaka, Masahumi Inomata, Mitsuo Shimada, Hideo Baba, Kazuhiko Koike, Masao Omata, Masatoshi Makuuchi, Yutaka Matsuyama, Norihiro Kokudo, Kiyoshi Hasegawa. Medical Expenditures and Treatment Efficacy of Patients who had Initial Hepatocellular Carcinoma and Underwent Surgery or Radiofrequency Ablation: Accompanying Research of the SURF Trial. ESMO2022.
Tatsuya Yamashita, Yoshikuni Kawaguchi, Shuichi Kaneko, Tadatoshi Takayama, Namiki Izumi, Naoki Yamanaka, Masatoshi Kudo, Mitsuo Shimada, Masafumi Inomata, Hideo Baba, Kazuhiko Koike, Masao Omata, Masatoshi Makuuchi, Yutaka Matsuyama, Norihiro Kokudo, Kiyoshi Hasegawa. A multicenter, non-randomized, controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF-Cohort Trial): Analysis of overall survival. 2022 ASCO Annual Meeting (June 3 - June 7, 2022).
Takashi Masuda, Yuichi Endo, Kiyoshi Hasegawa, Yoshikuni Kawaguchi, Tadatoshi Takayama, Namiki Izumi, Naoki Yamanaka, Masatoshi Kudo, Mitsuo Shimada, Shuichi Kaneko, Hideo Baba, Kazuhiko Koike, Masao Omata, Masatoshi Makuuchi, Yutaka Matsuyama, Masafumi Inomata, Norihiro Kokudo: SURF trial group. Comparative study of laparoscopic hepatectomy, open hepatectomy, and percutaneous radiofrequency ablation for small hepatocellular carcinoma: an ancillary study of randomized controlled trial (SURF trial). IHPBA（International HPB association world congress）24, Supp 1, S134, 2021.
Masatoshi Kudo, Kiyoshi Hasegawa, Yoshikuni Kawaguchi, Tadatoshi Takayama, Namiki izumi, Naoki Yamanaka, Mitsuo Shimada, Masafumi Inomata, Shuichi Kaneko, Hideo Baba, Kazuhiko Koike, Masao Omata, Masatoshi Makuuchi, Yutaka Matsuyama, Norihiro Kokudo. A multicenter randomized controlled trial to evaluate the efficacy of SUrgery vs. RadioFrequency ablation for small hepatocellular carcinoma (SURF TRIAL): Analysis of Overall Survival. 2021 ASCO Annual Meeting. June 4-8, 2021
Sawamoto R, Matsuyama Y. Standardized mortality ratio-weighted power prior approach for covariate-adjusted borrowing of historical control data. 2021 Joint Statistical Meetings, Online. Aug 2021.
Sakamoto A, Aizawa K, Uemura K, Komuro I, Matsuyama Y, Nagai R. Increased serum immunoglobulin G4 level is a novel predictor of cardiovascular events independent of established risk factors: Results from the REAL-CAD study. American Heart Association Scientific Sessions 2020 November 14-16, Dallas, Texas
Sakamoto A, Aizawa K, Uemura K, Komuro I, Matsuyama Y, Nagai R. Increased serum immunoglobulin G4 level is a novel predictor of cardiovascular events independent of established risk factors: Results from the REAL-CAD study. American Heart Association Scientific Sessions 2020 November 14-16, Dallas, Texas
Hagiwara Y, Kawahara T, Shiroiwa T. What is a valid mapping algorithm in cost-utility analyses? An answer from a missing data perspective. International Society for Pharmacoeconomics and Outcome Research Europe 2019. Copenhergen, Denmark. November 2019. PNS323.
Kashiwabara K, Matsuyama Y. Treatment effect estimation in an efficient adaptive design: comparison with the exact estimation method. 40th Annual Conference of the ISCB 2019, 14-18 July, Leuven, Belgium.
Satoi S, Unno M, Motoi F, Matsuyama Y, Matsumoto I, Aosasa S, Shirakawa H, Wada K, Fujii T, Yoshitomi H, Takahashi S, Sho M, Ueno H, Yamamoto H, Kosuge T. The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (Randomized phase II/III trial; Prep-02/JSAP-05). ASCO 2019, May 31-June 4, Chicago, USA